ReviewIranian journal of pharmaceutical research : IJPR
Vancomycin Insights: An Update on Mechanism, Activity, Toxicity, Resistance, and Novel Drug Delivery Systems.
Review in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intrawound Vancomycin Powder in Surgical Site Infection Prophylaxis: A Comprehensive Review of Mechanisms, Efficacy, Safety, and Clinical Controversies.Advances in therapy · 2026Review
- Machine learning studies of drug-induced nephrotoxicity: a scoping review.Therapeutic advances in drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Vancomycin is an important antibiotic with a glycopeptide structure, effective against gram-positive bacterial infections through the inhibition of bacterial cell wall biosynthesis. It is indicated for the treatment of serious complicated skin, bloodstream, lower respiratory tract, bone, and joint infections. Primarily administered intravascularly, vancomycin shows negligible oral bioavailability. This review discusses the mechanism of action and toxicity of vancomycin, along with resistance issues and the mechanisms involved. Evidence Acquisition: We covered updated literature regarding various delivery systems for vancomycin, including nanoparticles, nanofibers, microparticles, liposomes, and hydrogels. Their antimicrobial evaluations and significant results are presented, alongside summaries of attempts for vancomycin oral delivery. The main issues of vancomycin, such as poor physicochemical properties (high molecular mass and aqueous solubility), poor oral bioavailability, minimum inhibitory concentration (MIC) creep, emergence of resistance, and high tendency to accumulate in the kidneys, can be addressed using novel drug delivery systems. Results and Conclusions: We summarized a range of novel drug delivery systems that have been investigated for enhancing the efficacy of vancomycin. The data collected here could be used as a guide for fabricating proper carriers for vancomycin delivery and selecting appropriate antimicrobial tests. Further in-depth studies on the mechanisms by which nanoparticles overcome resistance and enhance drug efficacy may pave the way for designing more effective systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.